Replimune to resubmit RP1 BLA after FDA alignment on path forward

Replimune announced it will resubmit its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma following productive FDA discussions, with the agency committing to prioritize review. The development signals regulatory progress for the company's lead oncolytic immunotherapy candidate in a market with significant unmet patient need.